Brief: Atossa Unveils Regulatory Strategy to Fast-Track (Z)-Endoxifen for Breast Cancer Risk Reduction
08/09/2025 13:48
Sept 8 (Reuters) - Atossa Therapeutics Inc ATOS.O: ATOSSA THERAPEUTICS ANNOUNCES REGULATORY STRATEGY AIMED AT ACCELERATING DEVELOPMENT OF LOW-DOSE (Z)-ENDOXIFEN FOR BREAST CANCER RISK REDUCTION ATOSSA THERAPEUTICS INC - REQUESTS TYPE C MEETING WITH FDA ATOSSA THERAPEUTICS INC - EXPECTS MEETING OUTCOME UPDATE BY YEAR-END 2025 Source text: ID:nPn3V57Gva Further company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary